重庆智翔金泰生物制药股份有限公司 自愿披露关于GR1802注射液启动过敏性鼻炎适应症III期临床试验的公告

Group 1 - The company has completed communication with the National Medical Products Administration (NMPA) regarding the initiation of a Phase III clinical trial for GR1802 injection in patients with seasonal allergic rhinitis [1][2] - GR1802 injection is a recombinant fully human anti-IL-4Rα monoclonal antibody, targeting IL-4Rα, which inhibits Th2-type inflammatory responses mediated by IL-4 or IL-13 [1] - The drug has received clinical trial approval for multiple indications, including moderate to severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria, with allergic rhinitis now entering Phase III trials [2] Group 2 - As of the announcement date, only two drugs targeting the same receptor have been approved for marketing in China [3] - The drug must complete clinical trials and submit a new drug application to obtain a marketing authorization before it can be sold [3]